Literature DB >> 10604992

The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation.

M L Baroja1, D Luxenberg, T Chau, V Ling, C A Strathdee, B M Carreno, J Madrenas.   

Abstract

CTLA-4 is a negative regulator of T cell responses. Sequence analysis of this molecule reveals the presence of two cytoplasmic tyrosine residues at positions 165 and 182 that are potential Src homology (SH)-2 domain binding sites. The role of phosphorylation of these residues in CTLA-4-mediated signaling is unknown. Here, we show that sole TCR ligation induces zeta-associated protein (ZAP)-70-dependent tyrosine phosphorylation of CTLA-4 that is important for cell surface retention of this molecule. However, CTLA-4 tyrosine phosphorylation is not required for down-regulation of T cell activation following CD3-CTLA-4 coengagement. Specifically, inhibition of extracellular signal-regulated kinase (ERK) activation and of IL-2 production by CTLA-4-mediated signaling occurs in T cells expressing mutant CTLA-4 molecules lacking the cytoplasmic tyrosine residues, and in lck-deficient or ZAP-70-deficient T cells. Therefore, CTLA-4 function involves interplay between two different levels of regulation: phosphotyrosine-dependent cell surface retention and phosphotyrosine-independent association with signaling molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604992     DOI: 10.4049/jimmunol.164.1.49

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 2.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 3.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 4.  Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation.

Authors:  Laura L Carter; Beatriz M Carreno
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Stomatin-like protein 2 binds cardiolipin and regulates mitochondrial biogenesis and function.

Authors:  Darah A Christie; Caitlin D Lemke; Isaac M Elias; Luan A Chau; Mark G Kirchhof; Bo Li; Eric H Ball; Stanley D Dunn; Grant M Hatch; Joaquín Madrenas
Journal:  Mol Cell Biol       Date:  2011-07-11       Impact factor: 4.272

Review 6.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

7.  Characterization of human peritoneal dendritic cell precursors and their involvement in peritonitis.

Authors:  M L McCully; T A Chau; P Luke; P G Blake; J Madrenas
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 8.  SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.

Authors:  Ulrike Lorenz
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription.

Authors:  M Srahna; L A Van Grunsven; J E Remacle; P Vandenberghe
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

10.  Structure-Function analysis of the CTLA-4 interaction with PP2A.

Authors:  Wendy A Teft; Thu A Chau; Joaquín Madrenas
Journal:  BMC Immunol       Date:  2009-04-30       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.